Drugs News and Research

RSS

Cancer cells 'addicted' to self-preservation process

A team of investigators at The Cancer Institute of New Jersey (CINJ); Rutgers, The State University of New Jersey; and Princeton University, have determined that cancer cells are "addicted" to a self-preservation process known as autophagy. They also showed that the inhibition of that process could prove to be a valuable treatment approach for aggressive cancers. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

11 Feb 2011

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

A three-year, $3 million gift from the Richard J. Fasenmyer Foundation will fund research by a pair of Cleveland physicians into HIV and the body's response in autoimmune diseases.

11 Feb 2011

New trial tests surgery for Type 2 diabetes

A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for Type 2 diabetes. The aim of the study is to understand whether surgery can control diabetes, as well or even better than the best medical treatment available today. This is the first study of its kind open to patients who are overweight or mildly obese.

11 Feb 2011

Study finds too low drug concentrations used for treatment of children with TB

The realization of medically treating different children uniquely may start with one of the deadliest diseases in existence: tuberculosis.

11 Feb 2011

Preladenant may offer new supplemental treatment for Parkinson's disease: Study

Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy, an international study led by the University of South Florida found.

11 Feb 2011

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

11 Feb 2011

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.

10 Feb 2011

Momenta reports fourth quarter 2010 net income of $36.3M vs. $14.7M net loss for fourth quarter 2009

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the fourth quarter and year ended December 31, 2010.

10 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

MEDTOX Scientific fourth quarter total revenues increase 25.7% to $25.0 million

MEDTOX Scientific, Inc. today announced fourth quarter and year-end results for the periods ended December 31, 2010.

10 Feb 2011

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

QLT Inc. today announced that QLT091001, an oral synthetic retinoid, has received positive opinions for two distinct Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for the treatment of the inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

10 Feb 2011

Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec

Alexion Pharmaceuticals, Inc. announced that it has purchased patents and assets from Germany-based Orphatec Pharmaceuticals GmbH related to an investigational therapy for patients with molybdenum cofactor deficiency (MoCD) Type A, a devastating ultra-rare genetic disorder characterized by severe brain damage and rapid death in newborns.

10 Feb 2011

Indiana University creates Institute for Personalized Medicine

Indiana University has announced a major commitment to research in one of health care's most promising fields with the creation of the Indiana Institute for Personalized Medicine.

10 Feb 2011

Rhabdomyolysis episode at University of Iowa signals a public health crisis

On January 26, 2011, it was reported that 13 University of Iowa football players were affected so severely by rhabdomyolysis that they were hospitalized. Occurrences of rhabdomyolysis—muscle breakdown—are so rare that it suggests an additional causal factor, such as a drug.

10 Feb 2011

Idenix announces updates on HCV and HIV clinical development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs.

10 Feb 2011

Global Hygiene Council: Three simple steps to keep your family protected against infections

The Global Hygiene Council, a group of leading health and hygiene experts from around the world, convened in collaboration with the Centers for Disease Control and Prevention to discuss how proper hygiene plays a critical role in preventing the spread of illness and improving health around the world.

10 Feb 2011

Diamyd's NP2 Enkephalin Phase II study in cancer pain posted on ClinicalTrials.gov

Diamyd Medical´s US Phase II clinical trial, evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain, is posted on the ClinicalTrials.gov website.

10 Feb 2011

Florida pain clinic society opposes Gov. Scott's proposal to repeal Prescription Drug Monitoring Program

The Florida Society of Pain Management Providers opposes Governor Scott's proposal to repeal the Prescription Drug Monitoring Program (PDMP). The PDMP system is the single most important weapon in the war on Rx drug abuse, not only in Florida but in the other 42 states where legislators have approved their operation.

10 Feb 2011

Breakthrough in cancer research can help reduce heart failure, increase survival rates

A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.

10 Feb 2011

UCSD: Medication education can help patients with diabetes better stick to drug treatment plans

Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego say that medication education is a key factor in helping patients with diabetes better stick to their drug treatments plans.

10 Feb 2011

Drugs News and Research

Cancer cells 'addicted' to self-preservation process

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

New trial tests surgery for Type 2 diabetes

Study finds too low drug concentrations used for treatment of children with TB

Preladenant may offer new supplemental treatment for Parkinson's disease: Study

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Momenta reports fourth quarter 2010 net income of $36.3M vs. $14.7M net loss for fourth quarter 2009

Full genetic blueprint of multiple prostate tumors laid bare

MEDTOX Scientific fourth quarter total revenues increase 25.7% to $25.0 million

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec

Indiana University creates Institute for Personalized Medicine

Rhabdomyolysis episode at University of Iowa signals a public health crisis

Idenix announces updates on HCV and HIV clinical development programs

Global Hygiene Council: Three simple steps to keep your family protected against infections

Diamyd's NP2 Enkephalin Phase II study in cancer pain posted on ClinicalTrials.gov

Florida pain clinic society opposes Gov. Scott's proposal to repeal Prescription Drug Monitoring Program

Breakthrough in cancer research can help reduce heart failure, increase survival rates

UCSD: Medication education can help patients with diabetes better stick to drug treatment plans

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News